Literature DB >> 3874778

On the mechanism of deoxyribonucleoside toxicity in human T-lymphoblastoid cells. Reversal of growth inhibition by addition of cytidine.

Y Dahbo, S Eriksson.   

Abstract

High levels of deoxyadenosine and deoxyguanosine in patients with inherited deficiency of either adenosine deaminase or purine-nucleoside phosphorylase, respectively, are considered to be responsible for the associated immunological disorder. The mechanism involves phosphorylation to the corresponding deoxyribonucleoside triphosphates which subsequently inhibit the CDP-reducing activity of ribonucleotide reductase. Addition of deoxycytidine protects cells from the cytotoxic effects of deoxyadenosine and deoxyguanosine by competition for phosphorylation and by replenishing dCTP, the apparent limiting DNA precursor. Addition of cytidine, but not uridine, led to a reversal of deoxyguanosine and thymidine growth inhibition, comparable to that obtained with deoxycytidine. Analysis of the intracellular nucleotide pools showed that increased levels of cytidine ribonucleotides were sufficient to overcome the inhibitory effects of dGTP and dTTP on CDP reduction, thereby circumventing a depletion of the dCTP pool. A partial reversal of deoxyadenosine toxicity was also obtained with addition of cytidine. In this case little change in the dCTP level was observed, but a decreased dGTP pool appeared to be correlated with growth inhibition. High cytidine ribonucleotide levels partially prevented this effect. The present results may encourage the use of cytidine in combination with deoxycytidine as a pharmacological regime in treatment of immunodeficiency disease associated with increased deoxyribonucleotide levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874778     DOI: 10.1111/j.1432-1033.1985.tb09038.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

1.  Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations.

Authors:  M A Martinez; J P Vartanian; S Wain-Hobson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  HIV-1 protease inhibits its homologous reverse transcriptase by protein-protein interaction.

Authors:  M Böttcher; F Grosse
Journal:  Nucleic Acids Res       Date:  1997-05-01       Impact factor: 16.971

4.  Deoxycytidine deaminase-deficient Escherichia coli strains display acute sensitivity to cytidine, adenosine, and guanosine and increased sensitivity to a range of antibiotics, including vancomycin.

Authors:  Tina Manzhu Kang; Jessica Yuan; Alice Zhou; Casey Beppler; Jeffrey H Miller
Journal:  J Bacteriol       Date:  2014-03-14       Impact factor: 3.490

5.  Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors:  N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

6.  Induction of mutations in Drosophila melanogaster gypsy retroelements by modulation of intracellular deoxynucleoside triphosphate pools in vivo.

Authors:  Christophe Terzian; Michel Henry; Andreas Meyerhans; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

7.  Fate of direct and inverted repeats in the RNA hypermutagenesis reaction.

Authors:  V Pezo; M A Martinez; S Wain-Hobson
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

8.  Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.

Authors:  A Meyerhans; J P Vartanian; C Hultgren; U Plikat; A Karlsson; L Wang; S Eriksson; S Wain-Hobson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

9.  SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP.

Authors:  Tamara Davenne; Jenny Klintman; Sushma Sharma; Rachel E Rigby; Henry T W Blest; Chiara Cursi; Anne Bridgeman; Bernadeta Dadonaite; Kim De Keersmaecker; Peter Hillmen; Andrei Chabes; Anna Schuh; Jan Rehwinkel
Journal:  Cell Rep       Date:  2020-05-12       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.